| Literature DB >> 31316471 |
Domenico Corica1, Tommaso Aversa1, Rosaria Maddalena Ruggeri2, Mariateresa Cristani3, Angela Alibrandi4, Giorgia Pepe1, Filippo De Luca1, Malgorzata Wasniewska1.
Abstract
Background: Advanced glycation end-products (AGEs) and their cell receptor (RAGE) are involved in the pathophysiology of cardio-metabolic diseases. Interaction of AGEs with RAGE results in increased generation of oxygen radicals and pro-inflammatory cytokines. Circulating soluble RAGE (sRAGE) interacts with AGEs in order to counterbalance the negative effects of AGEs-RAGE interaction.Entities:
Keywords: AGEs/sRAGE-ratio; advanced glycation end-products; advanced oxidation-protein products; cardiometabolic risk; oxidative stress; sRAGE
Year: 2019 PMID: 31316471 PMCID: PMC6611173 DOI: 10.3389/fendo.2019.00426
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Comparison analysis of clinical data and cardio-metabolic risk factors between groups.
| Age (years) | 10.5 (5–16) | 10.8 (5.5–15.4) | 0.09 |
| Male/Female (%) | 48.8/51.2 | 33.3/66.7 | 0.17 |
| Pre-pubertal/Pubertal (%) | 51.2/48.8 | 48.1/51.9 | 0.08 |
| BMI SD | 2.1 (1.7–3.4) | 0.41 (-1.4–1.7) | 0.000 |
| TC (mg/dl) | 154 (123–238) | 153 (112–193) | 0.30 |
| LDL (mg/dl) | 88 (51–169) | 78 (58–122) | 0.07 |
| HDL (mg/dl) | 45 (25–119) | 56 (35–69) | 0.002 |
| TC/HDL-ratio | 3.42 (1.6–5.5) | 2.59 (1.8–4.8) | 0.000 |
| TG (mg/dl) | 71 (36–228) | 60 (41–136) | 0.01 |
| TG/HDL-ratio | 1.5 (0.6–6.5) | 1.1 (0.7–3.6) | 0.001 |
| AIP | −0.2 (-0.6–0.5) | −0.3 (-0.5–0.2) | 0.001 |
| HOMA-IR | 2.32 (0.7–6.3) | 1.34 (0.8–3.5) | 0.003 |
| TSH (μlU/ml) | 2.3 (0.6–7.98) | 2.0 (1.3–5.3) | 0.76 |
| GPT (U/L) | 17 (8–69) | 14 (6–27) | 0.000 |
| GOT (U/L) | 23 (16–37) | 23 (17–32) | 0.41 |
| CRP (mg/dl) | 0.2 (0.1–1.6) | 0.1 (0.1–0.9) | 0.008 |
| Uric Acid (mg/dl) | 4.6 (3.2–7.5) | 4 (2.9–5) | 0.000 |
| sRAGE | 393.3 (183.3–831.3) | 558.3 (265.8–1132.3) | 0.000 |
| AGEs | 149 (75.5–292) | 139.3 (94.1–251.1) | 0.36 |
| AOPPs | 1.6 (0.6–4.4) | 1.2 (0.8–2.3) | 0.000 |
| AGEs/sRAGE-ratio | 0.4 (0.2–1.2) | 0.3 (0.1–0.6) | 0.001 |
Comparison analysis was performed by Mann-Whitney test for numerical variables (expressed as median and range) and by Chi-Square test for categorical variables (gender and pubertal stage).
Group A, overweight and obese patients (BMI ≥ 1 SD); Group B, healthy matched controls (BMI <1 SD).
TC, Total cholesterol; TG, Triglycerides; AIP, Atherogenic index of plasma; HOMA-IR, Homeostasis model assessment of insulin resistance; CRP, C-reactive protein; AGEs, Advanced glycation end-products; sRAGE, Circulating soluble AGE receptor; AOPPs, Advanced oxidation-protein products.
Figure 1Box-plot of oxidative stress markers in groups A (overweight/obese) and B (controls).
Correlation analysis among oxidative stress markers and cardio-metabolic risk factors (Spearman's test).
| BMI SD | −0.52 | 0.72 | 0.46 | 0.42 | |
| 0.53 | |||||
| WHtR | −0.2 | 0.07 | −0.01 | 0.19 | |
| 0.21 | 0.65 | 0.95 | 0.22 | ||
| TC | −0.10 | 0.08 | 0.09 | 0.19 | |
| 0.38 | 0.47 | 0.50 | 0.09 | ||
| LDL | −0.12 | 0.23 | 0.16 | 0.28 | |
| 0.31 | 0.20 | ||||
| HDL | 0.30 | −0.17 | −0.47 | −0.33 | |
| 0.15 | |||||
| TC/HDL–ratio | −0.33 | 0.23 | 0.47 | 0.41 | |
| TG | −0.05 | 0.15 | 0.52 | 0.14 | |
| 0.65 | 0.23 | 0.24 | |||
| TG/HDL-ratio | −0.18 | 0.20 | 0.54 | 0.25 | |
| 0.12 | n.s. | ||||
| AIP | −0.18 | 0.19 | 0.54 | 0.25 | |
| 0.11 | 0.09 | ||||
| HOMA-IR | −0.20 | −0.60 | 0.37 | 0.13 | |
| 0.10 | 0.63 | 0.28 | |||
| CRP | −0.26 | 0.23 | 0.39 | 0.40 | |
| Uric acid | −0.11 | 0.06 | 0.08 | 0.16 | |
| 0.35 | 0.58 | 0.50 | 0.17 |
WHtR, Waist-to-height-ratio; TC, Total cholesterol; TG, Triglycerides; AIP, Atherogenic index of plasma; HOMA-IR, Homeostasis model assessment of insulin resistance; CRP, C-reactive protein; AGEs, Advanced glycation end-products; sRAGE, Circulating soluble AGE receptor; AOPPs, Advanced oxidation-protein products. Bold values indicate a statistically significant correlation.
Figure 2Correlation between oxidative stress markers and BMI SD.
Statistically significant associations at univariate linear regression analysis.
| TC/HDL-ratio | 14.07 | 0.02 |
| LDL | 0.59 | 0.03 |
| Triglycerides | 0.45 | 0.01 |
| AIP | 54.12 | 0.03 |
| BMI SD | −67.12 | 0.000 |
| TC/HDL-ratio | −56.31 | 0.015 |
| BMI SD | 0.202 | 0.000 |
| HOMA-IR | 0.123 | 0.03 |
| Triglycerides | 0.01 | 0.000 |
| HDL | −0.012 | 0.02 |
| TC/HDL-ratio | 0.24 | 0.001 |
| AIP | 1.395 | 0.000 |
| CRP | 0.55 | 0.01 |
| BMI SD | 0.062 | 0.000 |
| TC/HDL-ratio | 0.065 | 0.008 |
| CRP | 0.214 | 0.002 |
TC, Total cholesterol; AIP, Atherogenic index of plasma; HOMA-IR, Homeostasis model assessment of insulin resistance; CRP, C-reactive protein; AGEs, Advanced glycation end-products; sRAGE, Circulating soluble AGE receptor; AOPPs, Advanced oxidation-protein products.
Statistically significant associations at multivariate stepwise regression analysis for BMI SD, HOMA-IR, TC/HDL-ratio, LDL, Triglycerides, uric acid, CRP.
| Triglycerides | 0.618 | 0.01 |
| BMI SD | −73.18 | 0.000 |
| BMI SD | 0.13 | 0.02 |
| CRP | 0.522 | 0.008 |
| Triglycerides | 0.010 | 0.000 |
| BMI SD | 0.06 | 0.008 |
| CRP | 0.160 | 0.03 |
CRP, C-reactive protein; AGEs, Advanced glycation end-products; sRAGE, Circulating soluble AGE receptor; AOPPs, Advanced oxidation-protein products.